Brentuximab Vedotin for Treating CD30-Positive Hodgkin Lymphoma (TA446)

Technology Appraisal Guidance No. 446

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

they have relapsed or refractory disease after autologous stem cell transplant and

the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.

1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

  • they have relapsed or refractory disease after at least 2 previous therapies and
  • they cannot have autologous stem cell transplant or multi-agent chemotherapy and
  • the conditions of the managed access agreement are followed.

1.3 These recommendations are not intended to affect treatment with brentuximab vedotin that was started in the NHS before this guidance was published. Adults having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.


A copy of the full document and background is available on the Internet at www.nice.org.uk/guidance/ta446

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma.
Issue Date: June 2017


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases